

# Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery

*Sebastien Benizri,<sup>a,b,c</sup> Ludivine Ferey,<sup>a,b,c</sup> Bruno Alies,<sup>a,b,c</sup> Naila Mebarek,<sup>a,b,c</sup> Gaelle Vacher,<sup>a,b,c</sup>  
Ananda Appavoo,<sup>a,b</sup> Cathy Staedel,<sup>a,b,c</sup> Karen Gaudin,<sup>a,b,c</sup> and Philippe Barthélémy\*<sup>a,b,c</sup>*

<sup>a</sup>Univ. Bordeaux, ARNA laboratory, F-33000 Bordeaux, France.

<sup>b</sup>INSERM, U1212, ARNA laboratory, F-33000 Bordeaux, France.

<sup>c</sup>CNRS, UMR 5320, ARNA laboratory, F-33000 Bordeaux, France.

\* Correspondence: Philippe Barthélémy

ARNA Laboratory, team ChemBioPharm, U1212 INSERM - UMR 5320 CNRS, 146 rue Léo Saignat  
33076 Bordeaux Cedex, France.

Tel +33 (0)5 57 57 48 53

Email [philippe.barthelemy@inserm.fr](mailto:philippe.barthelemy@inserm.fr)

## Supporting Information


### HPLC analysis of SLNs

A reversed phase UHPLC method was developed to study SLN composition and chemical stability.


The separation was carried out with the column Synchronis C18 50 x 2.1 mm, 1.7  $\mu$ m. The mobile phase consisted of 70/30 MeOH/26.5 mM ammonium acetate (pH = 7.4) (A) and 25 mM ammonium acetate in MeOH (pH 7.9) (B). A flow rate of 0.2 mL/min was used and the gradient profile was 0-2 min, 0-100% B; 2-20 min, 100% B. The column temperature was set

at 25°C. The detection was performed at 267 nm for Sorafenib and diC<sub>16</sub>dT, and 257 nm for DOTAU. The injected volume was 1.0 µL leading to quantitation limits of 0.6 ng for Sorafenib and 15 ng for both nucleolipids, DOTAU and diC<sub>16</sub>dT.


Standard curves for Sorafenib, DOTAU, and diC<sub>16</sub>dT in ethanol are shown in Figures SI1, SI2, and SI3, respectively. The HPLC analyses of both formulations are presented in Figure SI4.




**Figure SI1** Standard curve Sorafenib:  $A = f(C)$  (UV 267 nm)



**Figure SI2** Standard curve DOTAU:  $A = f(C)$  (UV 257 nm)




**Figure SI3** Standard curve diC<sub>16</sub>dT:  $A = f(C)$  (UV 267 nm)



**Figure SI4.** Simultaneous analysis of Sorafenib and nucleolipids: diC<sub>16</sub>dT (A) and DOTAU (B) in formulations.

#### Stability studies of Sorafenib/diC<sub>16</sub>dT formulations

A similar chemical stability study was carried out on Sorafenib and diC<sub>16</sub>dT in SLNs at 4°C and 37°C. As shown on figure SI5, Sorafenib and diC<sub>16</sub>dT remain stable over a period of one month at both temperatures.




**Figure SI5.** Chemical stability of Sorafenib and diC<sub>16</sub>dT in SLNs versus time at 4°C and 37°C.

The influence of dissolution solvent and temperature on DOTAU and diC<sub>16</sub>dT was investigated.


Then, the impact of the nature of dissolution solvent was investigated. Figure SI6 A & B presents the stability of DOTAU and diC<sub>16</sub>dT, respectively, in various solvents at 40°C. DOTAU was significantly more stable in ACN (only 10% of decrease over 3 days) than in H<sub>2</sub>O (50% of decrease over 3 days), MeOH (up to 90% of decrease over 3 days) or EtOH (up to 85% of decrease over only 1 day) (Figure SI6.A). On the contrary, diC<sub>16</sub>dT appeared stable over time whatever the solvent nature (Figure SI6.B).






**Figure SI6.** Chemical studies of DOTAU (A) and diC16dT (B) at 40°C in different solvents during time.


### SLN<sup>-</sup> - Pdl: 0.202




**Figure SI7.** Average Size of SLN<sup>-</sup> measure by DLS




**Figure SI8.** EDX spectra at SLN- (up) and on the copper grid (down)




**Figure S19.** Colloidal stability of SLN<sup>-</sup> measuring by DLS experiments




**Figure SI10.** Zeta potential after 7 days (left) and 30 days (right) at 4°C and 37°C for SLN<sup>+</sup> (up) and SLN<sup>-</sup> (down)



**Figure S111.** Cell morphology assessed by phase contrast microscopy on carcinoma cell lines in the absence of Sorafenib (control), with 5  $\mu$ M of free Sorafenib, with SLN<sup>-</sup> at 4  $\mu$ M and SLN<sup>+</sup> at 2.8  $\mu$ M upon 4 days of treatment.



**Figure SI12.** Representative dot plots of cell granularity (SSC-A) against PE-Texas Red-A detection after 4 days of HuH7 incubation with SLN+ loaded with Sorafenib at different concentrations (0, 1, 5, 10, 25, 50 and 100  $\mu$ M). The percentage of PE-Texas Red positive cells were quantified by FACS. Control corresponds to HuH7 without Ethidium homodimer-1 dye.



**Figure SI13.** HuH7 cells lines with SLN<sup>+</sup> at 50  $\mu$ M. Calcein were used to stain live cells and ethidium stain dead cells.